Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report
Malignant melanoma is a malignant tumor with a poor prognosis. From 2010 the discovery of mutation of BRAF and the development of drugs against this target significantly improved the survival of these patients. The best results were achieved with the double inhibition of the MAPK pathway. There are 3 approved targeted therapies: vemurafenib and cobimetinib, dabrafenib and trametinib, encorafenib and binimetinib. They have similar efficacy, but different toxicity profiles. In this article, is critically review the case of a patient with metastatic melanoma treated with the combination encorafenib and binimetinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 113(2022), 6 vom: 12. Juni, Seite 28e-30e |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Efficacia della combinazione encorafenib binimetinib in un caso clinico di melanoma metastatico BRAF mutato |
|---|
| Beteiligte Personen: |
Di Guardo, Lorenza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
181R97MR71 |
|---|
| Anmerkungen: |
Date Completed 28.06.2022 Date Revised 08.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3827.38162 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342791370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342791370 | ||
| 003 | DE-627 | ||
| 005 | 20231226014931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3827.38162 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342791370 | ||
| 035 | |a (NLM)35758129 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Di Guardo, Lorenza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report |
| 246 | 3 | 3 | |a Efficacia della combinazione encorafenib binimetinib in un caso clinico di melanoma metastatico BRAF mutato |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2022 | ||
| 500 | |a Date Revised 08.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Malignant melanoma is a malignant tumor with a poor prognosis. From 2010 the discovery of mutation of BRAF and the development of drugs against this target significantly improved the survival of these patients. The best results were achieved with the double inhibition of the MAPK pathway. There are 3 approved targeted therapies: vemurafenib and cobimetinib, dabrafenib and trametinib, encorafenib and binimetinib. They have similar efficacy, but different toxicity profiles. In this article, is critically review the case of a patient with metastatic melanoma treated with the combination encorafenib and binimetinib | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a binimetinib |2 NLM | |
| 650 | 7 | |a 181R97MR71 |2 NLM | |
| 650 | 7 | |a encorafenib |2 NLM | |
| 650 | 7 | |a 8L7891MRB6 |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 113(2022), 6 vom: 12. Juni, Seite 28e-30e |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2022 |g number:6 |g day:12 |g month:06 |g pages:28e-30e |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3827.38162 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2022 |e 6 |b 12 |c 06 |h 28e-30e | ||